Nektar Therapeutics

Stage 4 · Declining · week 2

As of Oct 22, 2026, Nektar Therapeutics is in Stage 4, the downtrend phase, now in week 2 (since Oct 13, 2026). It closed at $38.65, 61.5% below its 52-week high and below its 200-day average, which is falling.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. More about the company

$38.65

+1.58% today

$1.3B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NKTR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 18w

S4 29w

S2 22w

S2 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 1w → S1 9w → S4 12w → S1 7w → S2 18w → S3 10w → S2 2w → S3 4w → S2 4w → S3 2w → S4 29w → S1 3w → S2 22w → S3 10w → S2 13w → S3 10w → S2 7w → S3 2w → S4 1w current

Total tracked: 166 weeks across 19 stage runs.

NKTR among Biotechnology294th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…294	NKTRNektar Therapeutics	Stage 4 · wk 2	31	−33.0%

vs 52W High

-61.5%

$35.12 lo$100.35 hi

61.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-40.6%

200 DMA: $65.04 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.82x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-33.0%

-45.4%

-57.6%

YTD

-11.0%

-34.9%

Scan Membership

Breakout Watch

Latest: 2024-10-23

5 appearances in last 60 days. First seen: 2020-06-02.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.82x

2026-10-21S4

Wk 2 · Vol 0.49x

2026-10-20S4

Wk 2 · Vol 0.86x

2026-10-19S4

Wk 1 · Vol 0.68x

2026-10-16S4

Wk 1 · Vol 0.64x

2026-10-15S4

Wk 1 · Vol 0.56x

2026-10-14S4

Wk 1 · Vol 0.83x

2026-10-13S43→4

Wk 1 · Vol 1.73x

2026-10-12S3

Wk 2 · Vol 0.89x

2026-10-09S3

Wk 2 · Vol 1.01x

2026-10-08S3

Wk 2 · Vol 1.53x

2026-10-07S3

Wk 2 · Vol 1.34x

Moving averages & range

50 DMA

$60.01

200 DMA

$65.04

52W High

$100.35

52W Low

$35.12

5D Low

$35.78

Resistance levels (recent highs)

20d High

$60.55

60d High

$76.48

120d High

$86.89

250d High

$100.35

Next resistance

+56.7%

to 20d High

ROE

-35.8%

Profit margin -287.8%

Dividend Yield

0.00%

P/B 1.5

Nektar Therapeutics: quick answers

What stage is Nektar Therapeutics in?

As of Oct 22, 2026, Nektar Therapeutics (NKTR) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 13, 2026 and is in week 2. What the four stages mean

Is Nektar Therapeutics in an uptrend?

No. Nektar Therapeutics is in a Stage 4 downtrend. It trades 40.6% below its 200-day average, which is falling.

How far is Nektar Therapeutics from its 52-week high?

Nektar Therapeutics closed at $38.65 on Oct 22, 2026, 61.5% below its 52-week high of $100.35. Its 52-week low is $35.12.

How has Nektar Therapeutics performed over the past year?

As of Oct 22, 2026, Nektar Therapeutics is down 34.9% over the past year and down 11.0% so far in 2026.

Which sector and industry is Nektar Therapeutics in?

Nektar Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.